Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Oncology > 2026 Vol. 1 > No. 1 > 100007
Next Article Previous Article
COMMENTARY   Open Access     Cite

Rethinking how immunotherapy is combined with chemoradiotherapy in inoperable locally advanced esophageal squamous cell carcinoma

  • 1.

    Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China

  • 2.

    Department of Immunology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China

More Information
The Innovation Oncology  1(1),  https://doi.org/10.59717/j.xinn-oncol.2026.100007  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Zhang W., Zhang T., Chen X., et al. (2026). Iparomlimab and tuvonralimab (QL1706) combined definitive chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (QL1706-IIT-02): A single arm, phase 2 trial. EClinicalMedicine 92:103758. DOI:10.1016/j.eclinm.2026.103758

    View in Article CrossRef Google Scholar

    [2] Zhang W., Yan C., Zhang T., et al. (2021). Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: A phase 1b study. Oncoimmunology 10:1971418. DOI:10.1080/2162402x.2021.1971418

    View in Article CrossRef Google Scholar

    [3] Zhu Y., Wen J., Li Q., et al. (2023). Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): A single-arm, phase 2 trial. Lancet Oncol. 24:371−382. DOI:10.1016/s1470-2045(23)00060-8

    View in Article CrossRef Google Scholar

    [4] Chen B., Liu S., Zhu Y., et al. (2026). Tislelizumab combined with induction chemotherapy and concurrent chemoradiotherapy in locally advanced ssophageal squamous cell carcinoma: A multicenter, randomized, phase II trial (EC-CRT-002). J. Clin. Oncol. 0:JCO-25-03044. DOI:10.1200/jco-25-03044

    View in Article Google Scholar

    [5] Chau I., Cho B.C., Chen M.H., et al. (2025). 2094O SKYSCRAPER-07: A phase III, randomised study of atezolizumab (atezo) with or without tiragolumab (tira) in patients (pts) with unresectable esophageal squamous cell carcinoma (ESCC) that has not progressed following definitive concurrent chemoradiotherapy (dCRT). Ann. Oncol. 36:S1101−S1102. DOI:10.1016/j.annonc.2025.08.2716

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Zhang T., Yan C. and Zhang W. (2026). Rethinking how immunotherapy is combined with chemoradiotherapy in inoperable locally advanced esophageal squamous cell carcinoma. The Innovation Oncology 1:100007. https://doi.org/10.59717/j.xinn-oncol.2026.100007
    Zhang T., Yan C. and Zhang W. (2026). Rethinking how immunotherapy is combined with chemoradiotherapy in inoperable locally advanced esophageal squamous cell carcinoma. The Innovation Oncology 1:100007. https://doi.org/10.59717/j.xinn-oncol.2026.100007

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Supplementary Information

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(393) PDF downloads(254)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.